JP2021500071A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500071A5
JP2021500071A5 JP2020542539A JP2020542539A JP2021500071A5 JP 2021500071 A5 JP2021500071 A5 JP 2021500071A5 JP 2020542539 A JP2020542539 A JP 2020542539A JP 2020542539 A JP2020542539 A JP 2020542539A JP 2021500071 A5 JP2021500071 A5 JP 2021500071A5
Authority
JP
Japan
Prior art keywords
amino acid
cells
seq
vegf
trap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/056343 external-priority patent/WO2019079494A1/en
Publication of JP2021500071A publication Critical patent/JP2021500071A/ja
Publication of JP2021500071A5 publication Critical patent/JP2021500071A5/ja
Pending legal-status Critical Current

Links

JP2020542539A 2017-10-18 2018-10-17 ヒト翻訳後修飾vegf−trapによる眼疾患および転移性大腸がんの処置 Pending JP2021500071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574038P 2017-10-18 2017-10-18
US62/574,038 2017-10-18
PCT/US2018/056343 WO2019079494A1 (en) 2017-10-18 2018-10-17 TREATMENT OF OCULAR DISEASES AND METASTATIC COLON CANCER WITH A VEGF TRAP WITH HUMAN POST-TRANSLATIONAL MODIFICATION

Publications (2)

Publication Number Publication Date
JP2021500071A JP2021500071A (ja) 2021-01-07
JP2021500071A5 true JP2021500071A5 (cg-RX-API-DMAC7.html) 2021-12-16

Family

ID=64267910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542539A Pending JP2021500071A (ja) 2017-10-18 2018-10-17 ヒト翻訳後修飾vegf−trapによる眼疾患および転移性大腸がんの処置

Country Status (7)

Country Link
US (1) US20210010025A1 (cg-RX-API-DMAC7.html)
EP (1) EP3697449A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021500071A (cg-RX-API-DMAC7.html)
AU (1) AU2018350990A1 (cg-RX-API-DMAC7.html)
CA (1) CA3079565A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020003945A (cg-RX-API-DMAC7.html)
WO (1) WO2019079494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11766489B2 (en) * 2017-11-27 2023-09-26 4D Molecular Therapeutics, Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
JP7707081B2 (ja) * 2019-05-17 2025-07-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 網膜細胞を標的とした最適化された遺伝子治療
CN112342228B (zh) * 2019-08-09 2023-07-21 上海朗昇生物科技有限公司 表达抗vegf融合蛋白的aav病毒载体及其应用
CA3149401A1 (en) * 2019-08-26 2021-03-04 Stephen Joseph Pakola Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
CN114728169A (zh) * 2019-09-23 2022-07-08 麦考瑞大学 tau蛋白病的治疗
IL309560B2 (en) * 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022006751A (es) * 2019-12-06 2022-08-19 Regeneron Pharma Minitrampas de vegf y metodos de uso de las mismas.
MX2022013812A (es) * 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
AU2021313839A1 (en) * 2020-07-21 2023-03-23 FTGEN Corp Composition and method for treating eye diseases
US20230340529A1 (en) * 2020-09-03 2023-10-26 University Of Massachusetts Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
KR20230088630A (ko) * 2020-10-16 2023-06-20 자이로스코프 테라퓨틱스 리미티드 항-vegf 엔티티 및 음성 보체 조절인자를 코딩하는 핵산 및 연령-관련 황반 변성의 치료를 위한 그의 용도
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
CA3211476A1 (en) * 2021-03-31 2022-10-06 Hangzhou Exegenesis Bio Ltd. Fusion molecules targeting vegf and angiopoietin and uses thereof
AU2022253065A1 (en) * 2021-04-09 2023-09-28 Avirmax Biopharma Inc. Compositions and methods for ocular transgene expression
JP2025506383A (ja) * 2022-02-02 2025-03-11 アドヴェラム バイオテクノロジーズ, インコーポレイテッド アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法
AU2023250660A1 (en) * 2022-04-06 2024-10-24 Regenxbio Inc. Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
CN117304307A (zh) * 2022-06-27 2023-12-29 上海鼎新基因科技有限公司 一种治疗新生血管相关眼底疾病的aav药物
CN121772934A (zh) * 2023-08-01 2026-03-31 北京因诺惟康医药科技有限公司 融合多肽、包含其编码基因的表达盒、基因递送载体、药物组合物及用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT73101A (en) 1993-02-12 1996-06-28 Harvard College Method for regulating transcription of targeted genes and other biological events
ATE544776T1 (de) 1994-12-29 2012-02-15 Massachusetts Inst Technology Chimäre dna-bindeproteine
KR19990022651A (ko) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
JP2003524368A (ja) 1997-08-26 2003-08-19 アリアド ジーン セラピューティクス インコーポレイテッド ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、dna結合ドメインまたはリガンド結合ドメインを含む融合蛋白
IL134643A0 (en) 1997-08-27 2001-04-30 Ariad Gene Therapeutics Inc Chimeric transcriptional activators and compositions and uses related thereto
WO1999036553A2 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
JP2002503667A (ja) 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US10738326B2 (en) 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
EP2970946A4 (en) 2013-03-13 2016-09-07 Philadelphia Children Hospital ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
HUE052676T2 (hu) 2013-10-11 2021-05-28 Massachusetts Eye & Ear Infirmary Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
KR102281881B1 (ko) * 2013-12-06 2021-07-27 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
ES2826566T3 (es) * 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
WO2016200543A2 (en) * 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
JP6913032B2 (ja) * 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
MX382540B (es) * 2015-06-28 2025-03-13 Allgenesis Biotherapeutics Inc Proteinas de fusion para inhibir la angiogenesis
IL262207B2 (en) * 2016-04-15 2026-01-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
CN117531025A (zh) * 2016-06-16 2024-02-09 阿德夫拉姆生物技术股份有限公司 使用aav2变体和阿柏西普治疗amd
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
JP2020510424A (ja) * 2017-02-28 2020-04-09 アドヴェラム バイオテクノロジーズ, インコーポレイテッド 改変aavカプシドおよびその使用

Similar Documents

Publication Publication Date Title
US20230057519A1 (en) Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF Fab
TWI904068B (zh) 核酸分子及其用途
JP2025039615A (ja) 変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法
JP2020028308A5 (cg-RX-API-DMAC7.html)
CN113766934B (zh) 用于玻璃体内递送的变体aav衣壳
JP2024015194A (ja) アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用
JP2022530006A (ja) 完全ヒト翻訳後修飾抗体による治療剤
JP2021500071A (ja) ヒト翻訳後修飾vegf−trapによる眼疾患および転移性大腸がんの処置
JP2021503914A5 (cg-RX-API-DMAC7.html)
CN110650733A (zh) 经过修饰的aav衣壳和其用途
US20200297869A1 (en) Sequential intravitreal administration of aav gene therapy to contralateral eyes
JP7654562B2 (ja) 線維芽細胞増殖因子23関連低リン血症性疾患の遺伝子療法
RU2018143411A (ru) Лечение комплемент-опосредуемых расстройств
AU2013308470B2 (en) AAV mediated aquaporin gene transfer to treat Sjogren's syndrome
JP2017529395A5 (cg-RX-API-DMAC7.html)
JP2017506230A (ja) 黄斑変性を処置し、予防するための組成物および方法
US20230391864A1 (en) Vectorized anti-tnf-alpha antibodies for ocular indications
TW202237644A (zh) 用於治療前庭神經鞘瘤相關症狀之抗vegf抗體構築體及相關方法
JP7674391B2 (ja) グルコース-6-ホスファターゼ(G6Pase-a)をコードする遺伝子治療用ベクター
WO2025103416A1 (zh) 用于老年相关性黄斑变性的治疗的基因治疗药物
AU2024322589A1 (en) Compositions and methods for expressing therapeutics
US20250288697A1 (en) Vectorized anti-tnf-alpha inhibitors for ocular indications
CN116568283A (zh) 用于治疗前庭神经鞘瘤相关症状的抗vegf抗体构建体和相关方法
JP2023548145A (ja) 眼の適応症に対するベクター化tnf-アルファアンタゴニスト
CN118085112B (zh) 抗多个vegf家族蛋白的融合蛋白及其应用